Estimation of the relative effectiveness and waning of the monovalent third dose of COVID-19 vaccine against hospital admission in France: a novel self-controlled case series analysis

Clicks: 19
ID: 331533
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #206 of 378 articles by views in american journal of epidemiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 378 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
We present a novel application of the SCCS method for estimating the effectiveness and waning of the third dose of COVID-19 monovalent vaccine in France. We used data on individuals hospitalised for COVID-19 between September 2021 and February 2022 from the Système National des Données de Santé. Only cases having received a 3rd dose of COVID-19 vaccine prior to or on the day of hospitalisation were included in the analysis. We developed a new SCCS model including only time post-dose 3 vaccination, with reference period 24-65 days post-vaccination to capture maximum vaccine protection. Time was split into short-term and long-term post-vaccination risk periods, including days 4-9 corresponding to minimum protection, and successive 7-day windows from day 66 post vaccination. The model included two exposure variables, representing short-term and long-term effects of vaccination. The analysis confirms the relative effectiveness of the third-dose COVID-19 vaccination, the waning of vaccine immunity though of limited extent, and possible effect modification related to virus strain, vaccine, vaccination history, age, and sex. The strengths and weaknesses of this approach are discussed. Suitably applied, the SCCS method may provide a useful method of analysis of vaccine effectiveness which automatically controls for time-invariant confounders.
Reference Key
openalex_W7220362282 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jérémie Botton, Yonas Ghebremichael‐Weldeselassie, Mounia N. Hocine, Paddy Farrington
Are you one of these authors? Claim your profile
Journal american journal of epidemiology
Year 2026
DOI
10.1093/aje/kwag250
URL
https://doi.org/10.1093/aje/kwag250
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.